What the trial was testing
The trial enrolled 117 patients with alzheimer's disease. The study was sponsored by University of Kansas Medical Center and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
Hippocampal blood flow rose only in APOE4 carriers who exercised.
Journal of Cerebral Blood Flow and Metabolism · 2021 · NCT02000583
These findings — that rise in hippocampal blood flow with exercise — only in hypertensive APOE4 carriers — were published in the Journal of Cerebral Blood Flow and Metabolism and represent the headline result of the study.
Researchers tracked outcomes across 117 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with alzheimer's disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Aerobic exercise is free and broadly recommended. APOE4 genetic testing is available through doctors and consumer services. The American Heart Association and Alzheimer's Association both recommend regular aerobic exercise for brain health. Ask your primary care doctor about a starter exercise plan, especially if you have high blood pressure.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open alzheimer's disease trials
Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis
The study will investigate the biomarkers of Aβ and Tau seeds in plasma detected by Alzheimer's disease (AD) related seeds quantitative detector (AD-seeds-detector), and their sensitivity and specificity in diagnosing AD, compared with those from age-matched cognitively normal controls, and those with other types of dementia. To perform a high throughput analysis of the amount of Aβ and Tau seeds, the investigators have developed an AD-seeds-detector, in which a fluorescence microplate reader was combined with an oscillating mixer or water-bath-type ultrasonicator.
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), and cognitively normal individuals. The main question it aims to answer is: • What is the sensitivity and specificity of XTR006 PET visual reading results compared to the truth standard across MCI, AD, and cognitively normal subjects? Participants will: * Receive XTR006 injection * Undergo PET/CT scanning